Anti-inflammatory treatment improves high-density lipoprotein function in rheumatoid arthritis

Heart

Volumn 103, Issue 10, 2017, Pages 766-773

  O'Neill, Francis ^a   Charakida, Marietta ^a   Topham, Eric ^a   McLoughlin, Eve ^a   Patel, Neha ^a   Sutill, Emma ^a   Kay, Christopher W M ^a   D'Aiuto, Francesco ^a   Landmesser, Ulf ^b   Taylor, Peter C ^c   Deanfield, John ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^c UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ARYLDIALKYLPHOSPHATASE; ENDOTHELIAL NITRIC OXIDE SYNTHASE; HIGH DENSITY LIPOPROTEIN; INFLIXIMAB; METHOTREXATE; PLACEBO; PREDNISOLONE; SUPEROXIDE; TUMOR NECROSIS FACTOR; ANTIRHEUMATIC AGENT; BIOLOGICAL MARKER;

ADULT; ANALYSIS OF VARIANCE; ARTICLE; BIOAVAILABILITY; CASE CONTROL STUDY; CHOLESTEROL TRANSPORT; CLINICAL ARTICLE; CONTROLLED STUDY; DAS28; DRUG DOSE INCREASE; ENZYME ACTIVITY; ENZYME SYNTHESIS; FEMALE; HUMAN; LIPID ANALYSIS; LIPOPROTEIN BLOOD LEVEL; MALE; MIDDLE AGED; PROTEIN ANALYSIS; PROTEIN FUNCTION; RANDOMIZED CONTROLLED TRIAL; RHEUMATOID ARTHRITIS; SIGNAL TRANSDUCTION; TURBIDIMETRY; ULTRAVIOLET SPECTROPHOTOMETRY; ARTHRITIS, RHEUMATOID; BLOOD; CARDIOVASCULAR DISEASES; COMBINATION DRUG THERAPY; COMPLICATION; DOSE RESPONSE; DRUG EFFECTS; FOLLOW UP; INTRAVENOUS DRUG ADMINISTRATION; RETROSPECTIVE STUDY; TREATMENT OUTCOME;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; BIOMARKERS; CARDIOVASCULAR DISEASES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; HUMANS; INFLIXIMAB; INFUSIONS, INTRAVENOUS; LIPOPROTEINS, HDL; MALE; METHOTREXATE; MIDDLE AGED; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84999027771     PISSN: 13556037     EISSN: 1468201X     Source Type: Journal    
DOI: 10.1136/heartjnl-2015-308953     Document Type: Article

References (30)

1. Meune C, Touzé E, Trinquart L, et al. Trends in cardiovascular mortality in patients with rheumatoid arthritis over 50 years: a systematic review and meta-analysis of cohort studies. Rheumatology (Oxford) 2009;48:1309-13.
2. del Rincón ID, Williams K, Stern MP, et al. High incidence of cardiovascular events in a rheumatoid arthritis cohort not explained by traditional cardiac risk factors. Arthritis Rheum 2001;44:2737-45.
3. Myasoedova E, Crowson CS, Kremers HM, et al. Lipid paradox in rheumatoid arthritis: the impact of serum lipid measures and systemic inflammation on the risk of cardiovascular disease. Ann Rheum Dis 2011;70:482-7.
4. Charakida M, Besler C, Batuca JR, et al. Vascular abnormalities, paraoxonase activity, and dysfunctional HDL in primary antiphospholipid syndrome. JAMA 2009;302:1210-17.
5. McMahon M, Grossman J, FitzGerald J, et al. Proinflammatory high-density lipoprotein as a biomarker for atherosclerosis in patients with systemic lupus erythematosus and rheumatoid arthritis. Arthritis Rheum 2006;54:2541-9.
6. O'Neill FP, Riwanto M, Charakida M, et al. Structural and functional changes in HDL with low grade and chronic inflammation. Int J Cardiol 2015;188:111-16.
7. Taylor PC, Steuer A, Gruber J, et al. Ultrasonographic and radiographic results from a two-year controlled trial of immediate or one-year-delayed addition of infliximab to ongoing methotrexate therapy in patients with erosive early rheumatoid arthritis. Arthritis Rheum 2006;54:47-53.
8. Tong H, Knapp HR, VanRollins M. A low temperature flotation method to rapidly isolate lipoproteins from plasma. J Lipid Res 1998;39:1696-704.
9. Besler C, Heinrich K, Rohrer L, et al. Mechanisms underlying adverse effects of HDL on eNOS-activating pathways in patients with coronary artery disease. J Clin Invest 2011;121:2693-708.
10. Khera AV, Cuchel M, de la Llera-Moya M, et al. Cholesterol efflux capacity, highdensity lipoprotein function, and atherosclerosis. N Engl J Med 2011;364:127-35.
11. Bhattacharyya T, Nicholls SJ, Topol EJ, et al. Relationship of paraoxonase 1 (PON1) gene polymorphisms and functional activity with systemic oxidative stress and cardiovascular risk. JAMA 2008;299:1265-76.
12. O'Neill F, McLoughlin E, Riwanto M, et al. Reproducibility and biological variability of HDL's vascular functional assays. Atherosclerosis 2015;241:588-94.
13. González-Gay MA, González-Juanatey C. Inflammation and lipid profile in rheumatoid arthritis: bridging an apparent paradox. Ann Rheum Dis 2014;73:1281-3.
14. Hahn BH, Lourencço EV, McMahon M, et al. Pro-inflammatory high-density lipoproteins and atherosclerosis are induced in lupus-prone mice by a high-fat diet and leptin. Lupus 2010;19:913-17.
15. Popa C, van Tits LJ, Barrera P, et al. Anti-inflammatory therapy with tumour necrosis factor alpha inhibitors improves high-density lipoprotein cholesterol antioxidative capacity in rheumatoid arthritis patients. Ann Rheum Dis 2009;68:868-72.
16. Everett BM, Pradhan AD, Solomon DH, et al. Rationale and design of the Cardiovascular Inflammation Reduction Trial: a test of the inflammatory hypothesis of atherothrombosis. Am Heart J 2013;166:199-207.
17. Westlake SL, Colebatch AN, Baird J, et al. The effect of methotrexate on cardiovascular disease in patients with rheumatoid arthritis: a systematic literature review. Rheumatology (Oxford) 2010;49:295-307.
18. Tracey D, Klareskog L, Sasso EH, et al. Tumor necrosis factor antagonist mechanisms of action: a comprehensive review. Pharmacol Ther 2008;117: 244-79.
19. Filho AG, Kinote A, Pereira DJ, et al. Infliximab prevents increased systolic blood pressure and upregulates the AKT/eNOS pathway in the aorta of spontaneously hypertensive rats. Eur J Pharmacol 2013;700: 201-9.
20. Hürlimann D, Forster A, Noll G, et al. Anti-tumor necrosis factor-alpha treatment improves endothelial function in patients with rheumatoid arthritis. Circulation 2002;106:2184-7.
21. Wessels JA, Huizinga TW, Guchelaar HJ. Recent insights in the pharmacological actions of methotrexate in the treatment of rheumatoid arthritis. Rheumatology (Oxford) 2008;47:249-55.
22. Undurti A, Huang Y, Lupica JA, et al. Modification of high density lipoprotein by myeloperoxidase generates a pro-inflammatory particle. J Biol Chem 2009;284:30825-35.
23. Kageyama Y, Takahashi M, Ichikawa T, et al. Reduction of oxidative stress marker levels by anti-TNF-alpha antibody, infliximab, in patients with rheumatoid arthritis. Clin Exp Rheumatol 2008;26:73-80.
24. Bacchetti T, Campanati A, Ferretti G, et al. Oxidative stress and psoriasis: the effect of antitumour necrosis factor - a inhibitor treatment. Br J Dermatol 2013;168:984-9.
25. Huang Y, Wu Z, Riwanto M, et al. Myeloperoxidase, paraoxonase-1, and HDL form a functional ternary complex. J Clin Invest 2013;123:3815-28.
26. Voloshyna I, Seshadri S, Anwar K, et al. Infliximab reverses suppression of cholesterol efflux proteins by TNF-α: a possible mechanism for modulation of atherogenesis. Biomed Res Int 2014;2014:312647.
27. Rohatgi A, Khera A, Berry JD, et al. HDL cholesterol efflux capacity and incident cardiovascular events. N Engl J Med 2014;371:2383-93.
28. Ronda N, Greco D, Adorni MP, et al. Newly identified antiatherosclerotic activity of methotrexate and adalimumab: complementary effects on lipoprotein function and macrophage cholesterol metabolism. N Engl J Med 2015;67:1155-64.
29. White HD, Held C, Stewart R, et al. Darapladib for preventing ischemic events in stable coronary heart disease. N Engl J Med 2014;370:1702-11.
30. O'Donoghue ML, Braunwald E, White HD, et al. Effect of darapladib on major coronary events after an acute coronary syndrome: the SOLID-TIMI 52 randomized clinical trial. JAMA 2014;312:1006-15.